Related Experiment Video
Updated: Jan 26, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Recent Advances in the Management of Vascular Calcification in Patients with End-Stage Renal Disease
Kosaku Nitta1, Tetsuya Ogawa2, Norio Hanafusa3
1Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan, knitta@kc.twmu.ac.jp.
Insights
Vascular calcification (VC) in chronic kidney disease (CKD) patients is complex. Understanding treatments for VC, including novel therapies like magnesium and vitamin K, may improve outcomes for CKD patients on dialysis.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Vascular calcification (VC) is prevalent in chronic kidney disease (CKD), including end-stage renal disease (ESRD).
- VC contributes to arterial stiffening and cardiovascular mortality.
- CKD patients face traditional and non-traditional risk factors for VC.
Purpose of the Study:
- To review current treatment strategies and targets for managing VC in ESRD patients.
- To highlight the role of novel therapies such as magnesium and vitamin K supplementation.
- To emphasize the potential of improved VC management in reducing mortality rates.
Main Methods:
- Literature review of current therapeutic approaches for CKD-mineral bone disorder.
- Summary of conventional treatments: dietary phosphate restriction, phosphate binders, active vitamin D, and calcimimetics.
- Discussion of emerging therapies and their investigation in clinical trials.
Main Results:
- Conventional treatments for CKD-mineral bone disorder may inhibit VC progression but face challenges in achieving biochemical targets.
- Current strategies focus on managing calcium, phosphate, parathyroid hormone, and vitamin D levels.
- Fetuin-A's role in inhibiting VC by binding to calciprotein particles is highlighted.
Conclusions:
- Improved understanding and management of VC in CKD patients, particularly those on dialysis, could enhance survival rates.
- Novel therapeutic avenues, including magnesium and vitamin K, show promise.
- Fetuin-A represents a key factor in preventing mineral accretion in VC.
Background:
Vascular calcification (VC) is common in patients with chronic kidney disease (CKD) including end-stage renal disease (ESRD). The pathogenesis of VC is complex, resulting in increased arterial stiffening, which is associated with cardiovascular mortality. In addition to traditional cardiovascular risk factors, CKD patients also have a number of non-traditional cardiovascular risk factors that may play an important role in the pathogenesis of VC.
Summary:
Management of CKD-mineral bone disorder using conventional therapeutic approaches, which include restricting dietary phosphate, administering phosphate binders, and using active vitamin D and calcimimetics, may inhibit the progression of VC, but these approaches remain controversial because recommended biochemical targets are difficult to achieve. Current treatment strategies focus on correcting abnormal calcium, phosphate, parathyroid hormone, and vitamin D levels in ESRD patients. Novel therapies for addressing VC include magnesium and vitamin K supplementation, which are currently being investigated in randomized controlled trials. This review summarizes current treatment strategies and therapeutic targets for the management of VC in patients with ESRD. Key Messages: A better understanding of the potential therapeutic approaches to VC may lead to improved mortality rates among patients with CKD including those on dialysis. Fetuin-A inhibits VC by binding to the nanoparticles of calcium and phosphate, preventing mineral accretion. These particles are known as calciprotein particles and may provide an important pathway for mineral transport and clearance. This review article summarizes the current management of VC in patients with ESRD.
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Rheumatic Heart Disease III: Medical Management
Peripheral Artery Disease V: Postoperative Nursing Management

